Literature DB >> 23266750

A rare point mutation in the Ras oncogene in hepatocellular carcinoma.

Akinobu Taketomi1, Ken Shirabe, Jun Muto, Shohei Yoshiya, Takashi Motomura, Yohei Mano, Tohru Ikegami, Tomoharu Yoshizumi, Kenji Sugio, Yoshihiko Maehara.   

Abstract

PURPOSE: The Ras gene is one of the oncogenes most frequently detected in human cancers, and codes for three proteins (K-, N-, and H-Ras). The aim of this study was to examine the mutations in codons 12, 13 and 61 of the three Ras genes in cases of human hepatocellular carcinoma (HCC).
METHODS: Paired samples of HCC and corresponding non-malignant liver tissue were collected from 61 patients who underwent hepatectomy. A dot-blot analysis was used to analyze the products of the polymerase chain reaction (PCR) amplification of codons 12, 13, and 61 of K-, N- and H-Ras for mutations.
RESULTS: Only one mutation (K-Ras codon 13; Gly to Asp) was detected among the 61 patients. Interestingly, this patient had a medical history of surgery for both gastric cancer and right lung cancer. No mutations were found in codons 12 and 61 of K-Ras or codons 12, 13 and 61 of the N-Ras and H-Ras genes in any of the HCCs or corresponding non-malignant tissues.
CONCLUSIONS: These findings indicated that the activation of Ras proto-oncogenes by mutations in codons 12, 13, and 61 does not play a major role in hepatocellular carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23266750     DOI: 10.1007/s00595-012-0462-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  17 in total

Review 1.  Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2010-05-27       Impact factor: 3.402

Review 2.  Clinical aspects of hepatocellular carcinoma in Japan.

Authors:  Kiwamu Okita
Journal:  Intern Med       Date:  2006-04-03       Impact factor: 1.271

3.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.

Authors:  K Sugio; T Ishida; H Yokoyama; T Inoue; K Sugimachi; T Sasazuki
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

4.  Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing.

Authors:  M Tada; M Omata; M Ohto
Journal:  Cancer Res       Date:  1990-02-15       Impact factor: 12.701

Review 5.  Resection and liver transplantation for hepatocellular carcinoma.

Authors:  Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

6.  Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks.

Authors:  M Leon; M C Kew
Journal:  Anticancer Res       Date:  1995 May-Jun       Impact factor: 2.480

7.  Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma.

Authors:  N Ogata; T Kamimura; H Asakura
Journal:  Hepatology       Date:  1991-01       Impact factor: 17.425

Review 8.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.

Authors:  M Caraglia; G Giuberti; M Marra; R Addeo; L Montella; M Murolo; P Sperlongano; B Vincenzi; S Naviglio; S Del Prete; A Abbruzzese; P Stiuso
Journal:  Cell Death Dis       Date:  2011-04-28       Impact factor: 8.469

View more
  9 in total

1.  Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.

Authors:  Sufang Yang; Guohua Liu
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

2.  Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice.

Authors:  Zhuona Rong; Tingting Fan; Huiling Li; Juan Li; Kangwei Wang; Xinxin Wang; Jianyi Dong; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Mol Cell Proteomics       Date:  2017-05-16       Impact factor: 5.911

3.  Studies on the Contribution of Cox-2 Expression in the Progression of Oral Squamous Cell Carcinoma and H-Ras Activation.

Authors:  Abdolkarim Moazeni-Roodi; Abdolamir Allameh; Iraj Harirchi; Maziar Motiee-Langroudi; Ata Garajei
Journal:  Pathol Oncol Res       Date:  2016-09-15       Impact factor: 3.201

4.  Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study.

Authors:  Nazim Serdar Turhal; Berna Savaş; Öznur Çoşkun; Emine Baş; Bülent Karabulut; Deniz Nart; Taner Korkmaz; Dilek Yavuzer; Gökhan Demir; Gülen Doğusoy; Mehmet Artaç
Journal:  Mol Clin Oncol       Date:  2015-08-31

5.  Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy.

Authors:  Yang Ming Liu; Yu Xia; Wei Dai; Hua Ye Han; Yu Xue Dong; Jiong Cai; Xuan Zeng; Feng Yu Luo; Tao Yang; Yuan Zhi Li; Jie Chen; Jian Guan
Journal:  BMC Cancer       Date:  2014-11-28       Impact factor: 4.430

6.  Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.

Authors:  Wenmin Hou; Jibin Liu; Peizhan Chen; Hui Wang; Bang-Ce Ye; Fulin Qiang
Journal:  Oncol Lett       Date:  2014-06-13       Impact factor: 2.967

7.  STK33 promotes hepatocellular carcinoma through binding to c-Myc.

Authors:  Tian Yang; Bin Song; Jin Zhang; Guang-Shun Yang; Han Zhang; Wei-Feng Yu; Meng-Chao Wu; Jun-Hua Lu; Feng Shen
Journal:  Gut       Date:  2014-11-14       Impact factor: 23.059

Review 8.  The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA.

Authors:  Alistair Rice; Armando Del Rio Hernandez
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

9.  Role of the Mitochondrial Citrate-malate Shuttle in Hras12V-Induced Hepatocarcinogenesis: A Metabolomics-Based Analysis.

Authors:  Chuanyi Lei; Jun Chen; Huiling Li; Tingting Fan; Xu Zheng; Hong Wang; Nan Zhang; Yang Liu; Xiaoqin Luo; Jingyu Wang; Aiguo Wang
Journal:  Metabolites       Date:  2020-05-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.